Organic Polymers

Medchemexpress LLC 9-ING-41 | 1034895-42-5 | 99.13% | 404.35 | 100 MG

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

9-ING-41 (Elraglusib) is a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 0.71 μM. This compound significantly induces cell cycle arrest, autophagy, and apoptosis in cancer cells. It demonstrates anticancer activity and shows potential for enhancing the antitumor effects of chemotherapeutic agents.

• It is a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor.
• It leads to cell cycle arrest, autophagy, and apoptosis in cancer cells.
• It has anticancer activity.
• It has the potential for enhancing the antitumor effects of chemotherapeutic agents.

Medchemexpress LLC 9-Ing-41 (Elraglusib) | 1034895-42-5 | 404.35 | 10 MG

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

9-ING-41 (Elraglusib) is a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 0.71 μM. This compound leads to significant cell cycle arrest, autophagy, and apoptosis in cancer cells. It demonstrates anticancer activity and has potential for enhancing the antitumor effects of chemotherapeutic agents.

• Maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor
• IC50 of 0.71 μM against GSK-3β
• Significantly induces cell cycle arrest in cancer cells
• Promotes autophagy in cancer cells
• Leads to apoptosis in cancer cells
• Exhibits anticancer activity
• Potential to enhance antitumor effects of chemotherapeutic agents

eMolecules​ Medchem Express / 9-ING-41 / 5mg / 527574390 / HY-113914 / / 1034895-42-5 / [null] / 404.353 / C22H13FN2O5

Medchem Express / 9-ING-41 / 5mg / 527574390 / HY-113914 / / 1034895-42-5 / [null] / 404.353 / C22H13FN2O5